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Distribution-based measures of 
tumor heterogeneity are sensitive 
to mutation calling and lack strong 
clinical predictive power
Javad Noorbakhsh  1, Hyunsoo Kim1, Sandeep Namburi1 & Jeffrey H. Chuang  1,2
Mutant allele frequency distributions in cancer samples have been used to estimate intratumoral 
heterogeneity and its implications for patient survival. However, mutation calls are sensitive to the 
calling algorithm. It remains unknown whether the relationship of heterogeneity and clinical outcome 
is robust to these variations. To resolve this question, we studied the robustness of allele frequency 
distributions to the mutation callers MuTect, SomaticSniper, and VarScan in 4722 cancer samples from 
The Cancer Genome Atlas. We observed discrepancies among the results, particularly a pronounced 
difference between allele frequency distributions called by VarScan and SomaticSniper. Survival 
analysis showed little robust predictive power for heterogeneity as measured by Mutant-Allele Tumor 
Heterogeneity (MATH) score, with the exception of uterine corpus endometrial carcinoma. However, 
we found that variations in mutant allele frequencies were mediated by variations in copy number. Our 
results indicate that the clinical predictions associated with MATH score are primarily caused by copy 
number aberrations that alter mutant allele frequencies. Finally, we present a mathematical model 
of linear tumor evolution demonstrating why MATH score is insufficient for distinguishing different 
scenarios of tumor growth. Our findings elucidate the importance of allele frequency distributions as a 
measure for tumor heterogeneity and their prognostic role.
A major challenge for predicting clinical outcome to cancer treatment is the heterogeneity of cell populations 
within each tumor, as intratumoral heterogeneity is increasingly being associated with metastasis and resistance 
to therapies1–4. Intratumoral heterogeneity develops from mutations in cells and the relative growth advantages 
they confer to their descendant populations5,6. To better understand this phenomenon, multiple research groups 
have developed methods for the challenging problem of estimating tumor cellular composition from bulk tumor 
sequencing data7–13. These methods rely on the allele frequencies of mutations in each cancer, with low allele 
frequency mutations providing information on small subclones and high allele frequency mutations providing 
information on large subclones. Factors such as ploidy, copy number, and tumor purity can also affect this infer-
ence. In particular, aneuploidy in DNA mixtures has been associated with poor subclonal inference14. Still, accu-
rate measures of allele frequencies are central for evaluating subclonal heterogeneity and its clinical implications.
Increased heterogeneity has been theorized to lead to worse patient survival due to the increased potential 
for resistant populations15–17, but it remains unclear if current measures of tumor heterogeneity are sufficient to 
resolve such an effect. Prior studies have attempted to determine this relationship. For example, Rocco et al.18 used 
MATH score, a measure of the width of the allele frequency distribution, as a proxy for tumor heterogeneity and 
observed poorer survival for head and neck squamous cell carcinoma (HNSC) in patients with higher MATH 
score. More recently, Morris et al.19 found associations between heterogeneity and survival in several cancers 
using a multivariate regression of MATH and other variables versus survival. However, a key caveat is that all het-
erogeneity measures, including MATH, are affected by the accuracy of mutation calls. Many studies have shown 
that cancer mutation calls can differ substantially depending on the algorithm used for their determination20–23. 
In order to verify if heterogeneity impacts survival, it is necessary to quantify the robustness of allele frequency 
distributions to mutation callers as well as the robustness of their relationship to survival.
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Allele frequency distributions also provide information on the evolutionary processes in tumors, which 
remain poorly understood. While a variety of intratumoral evolutionary models have been proposed24–27, the 
impact of allele frequency accuracy on evolutionary inference has not been substantially explored. Determining 
the robustness of allele frequency distributions will elucidate this problem.
In this paper we study the robustness of allele frequency distributions and their relevance to patient survival. 
To the best of our knowledge this is the first study which explores sensitivity of these distributions and their 
clinical prognostic power to different mutation calling methods. We call single nucleotide variations (SNVs) 
from 11 cancer types in The Cancer Genome Atlas (TCGA) using three common mutation callers: MuTect28, 
SomaticSniper29, and VarScan30,31. To determine if the resulting allele frequency distributions are clinically useful, 
we analyze the correlation between these distributions and patient survival. Our study demonstrates whether 
allele frequency variability is clinically predictive and what other genomic features mediate these results. Finally, 
we discuss implications of a simple evolutionary mechanism on allele frequency distributions using a mathemat-
ical modeling approach.
Results
Different mutation callers lead to distinct allele frequency distributions. We analyzed a total of 
4722 samples from the TCGA database on a cloud computing platform to explore the effects of mutation calling 
by MuTect, SomaticSniper, and VarScan on allele frequency distributions and patient survival. Tumor/normal 
matched BAM files that had been aligned to the hg19 reference were used to call the SNVs (Fig. 1A). The muta-
tion calling pipelines (Fig. S1) were implemented by dockerizing32 each element of the pipeline and linking them 
through an interface provided by the Cancer Genome Cloud (CGC)33. Three different mutation calling pipelines 
were run for each tumor/normal pair on Amazon Web Services (AWS)34 through the CGC interface, and the 
resulting allele frequencies were calculated for each sample.
To analyze the range of possible allele frequency behaviors, we chose 11 cancer types from the TCGA database 
(Fig. 1B and Fig. S2), namely breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), glioblastoma 
multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), 
lung adenocarcinoma (LUAD), ovarian serous cystadenocarcinoma (OV), prostate adenocarcinoma (PRAD), 
skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), and uterine corpus endometrial carci-
noma (UCEC).
We found that overall MuTect called the largest number of SNVs and VarScan the least. On average, each sam-
ple called by MuTect had 1.4 times more SNVs compared to VarScan and 1.3 times compared to SomaticSniper 
(Fig. S3). On average, VarScan, SomaticSniper, and MuTect respectively called 1.5, 1.8, and 2.3 times more SNVs 
compared to the consensus SNVs (i.e. those called by all three mutation callers).
We then compared allele frequency distributions assessed by pairs of mutation callers using the 
Kolmogorov-Smirnov (KS) test (Fig. 2A,B). Distributions were not very robust across different cancer types 
(Fig. 2B). SomaticSniper and VarScan produced the most dissimilar allele frequency distributions with 42 ± 14% 
(mean ± std) of samples being significantly different across cancers. MuTect and VarScan produced the least dis-
similar results with 11 ± 8% of samples significantly different. This percentage was 22 ± 14% when MuTect was 
compared against SomaticSniper. Prostate adenocarcinoma (PRAD), showed unusually robust results, with only 
1%, 1%, and 3% of samples being significantly dissimilar when MuTect-SomaticSniper, MuTect-VarScan, and 
SomaticSniper-VarScan were compared pairwise, respectively.
Figure 1. Analysis design. (A) Schematic of the analysis process for 4722 TCGA samples. Somatic mutation 
calling was carried out on the NCI Cancer Genomics Cloud33, followed by additional local analysis. (B) Number 
of samples studied from each cancer.
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Due to sensitivity of the Kolmogorov-Smirnov test to the number of SNVs in the tumor (Fig. S4), we also used 
the earth mover’s distance (EMD) to assess differences between allele frequency distributions. EMD produced 
qualitatively similar results (Fig. 2C) to the Kolmogorov-Smirnov test, with SomaticSniper-VarScan showing 
the most difference among all pairwise comparisons and MuTect-VarScan showing the least difference. Another 
method based on cumulative absolute differences between pairs of distributions as well as a non-parametric test 
based on quadratic differences of distributions35 also yielded similar results (Fig. S5, and Methods). Across all can-
cers, per-sample correlation coefficient between allele frequencies of shared mutations was 0.97 ± 0.1, regardless 
of which pair of mutation callers were compared. Hence, differences between mutation caller results tend to be 
caused by disagreement about mutation calls rather than allele frequencies.
Copy number variations (CNV) can influence allele frequencies and may indirectly shape their distribution. 
To assess this effect, we repeated the analysis after removing somatic SNVs with copy number aberrations 
(|CNV| > 0.2). Here and throughout the text we use the CNV quantity to denote ( )log2 copy number2 , as provided by 
TCGA (see Methods). Comparison of allele frequency distributions using Kolmogorov-Smirnov statistics 
(Fig. S6) did not produce qualitatively different results from those shown in Fig. 2B, and again showed the most 
pan-cancer differences between SomaticSniper and VarScan. These results suggest that copy number impacts all 
mutation callers similarly.
MATH score is a poor predictor of patient survival across cancer types. To investigate the relation-
ship of tumor heterogeneity and survival, Mroz et al.18 introduced a measure of heterogeneity they term MATH. 
It is the ratio of scaled median absolute deviation (MAD) to median stated in percentage:
= ×MATH 100 MAD
Median (1)
We calculated this measure for all samples and mutation callers. Overall VarScan yielded higher median 
MATH score (35.4 ± 5.7) compared to SomaticSniper (24.4 ± 4.8) and MuTect (30.3 ± 5.9) (Fig. S7). Similar to 
Fig. 2, the MATH scores were also more similar between MuTect and SomaticSniper calls (pan-cancer Spearman 
correlation coefficient r = 0.7 ± 0.1) and more dissimilar between SomaticSniper and VarScan (r = 0.5 ± 0.2) 
(Fig. S7).
We then analyzed the relationship between MATH score and patient survival by grouping samples into high 
or low MATH groups as compared to the median of the cohort. These two groups were then compared using a 
log-rank test to determine the significance of MATH values on Kaplan-Meier patient survival curves (Fig. 3 and 
Fig. S8).
Among the cancers studied, COAD, OV, HNSC, and UCEC showed a significant (p < 0.05) relationship 
between MATH and survival for at least one caller (e.g. COAD p = 0.07, OV p = 0.02 with SomaticSniper calls). 
However, only UCEC showed a significant relationship for all three mutation callers (p = 0.00083, 0.0023, 
0.011 for MuTect, SomaticSniper, and VarScan calls, respectively). Although these results suggest some clinical 
Figure 2. Comparisons of allele frequency distributions for different mutation callers. (A) Distribution of 
Kolmogorov-Smirnov (KS) test p-values corresponding to the null hypothesis that mutation callers will produce 
similar allele frequency distributions, plotted pairwise for HNSC. The red dashed line indicates the Bonferroni 
corrected significance threshold α = .0 05. The percentage of samples that fall below this threshold are shown 
on each graph. (B) Percentage of significantly different samples for mutation caller pairs, grouped by cancer 
type. (C) Comparison of allele frequency distributions using earth mover’s distance.
www.nature.com/scientificreports/
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predictive power of MATH score, a more conservative approach would be to correct for multiple hypothesis 
testing. Using the Benjamini-Hochberg correction for all cancers and mutation callers led to significant results 
only for UCEC, and only when the calls were made by MuTect or SomaticSniper. Therefore the predictive power 
of MATH score is not robust in a pan-cancer analysis except for possibly UCEC.
Previous studies18,19 have shown a significant relationship between MATH score and patient survival in 
HNSC. We obtained similar results when the calls were made using MuTect; however the effect was not signifi-
cant when other callers were used (Fig. S8). Restricting the analysis to the same samples as in19 did not affect the 
significance of this result (Fig. S9). Thus the clinical predictive power of MATH in HNSC appears to be substan-
tially impacted by the mutation calling method.
To determine the direction of effect of MATH score on survival, we calculated the average survival difference 
between high and low MATH score groups (see Methods). This analysis indicates that for UCEC higher MATH 
score is associated with poorer patient survival (Fig. S10). The same trend is observed for COAD and HNSC. For 
OV, the direction of the trend is caller-dependent.
Copy number mediates prognostic power of allele frequency distributions. Allele frequency vari-
ation in a tumor is impacted by locus-to-locus copy number variation in addition to subclonal heterogeneity, and 
decomposing these two contributions may be important for clinical prognosis. We therefore repeated the above 
survival analysis but replaced MATH score with the standard deviation of CNV over mutated loci (Fig. 3B and 
Fig. S11). This CNV analysis yielded more robust results across mutation callers than the MATH score analysis 
(Fig. S12). Specifically, we found that copy number variation is correlated with survival in KIRC, OV, and UCEC 
for at least two mutation callers. Multiple hypothesis correction led to a robust effect in UCEC for all mutation 
callers as well as significance in OV for SomaticSniper and VarScan. This result indicates that copy number vari-
ation is a more robust predictor of patient survival than allele frequency distribution.
Despite the lack of statistical significance, for most cancers, higher CNV standard deviation led to poorer sur-
vival and this effect was robust across mutation callers (Fig. S10). This was most pronounced for SKCM, STAD, 
and UCEC. An exception was OV where higher copy number standard deviation was predictive of better survival.
To further distinguish the effect of allele frequencies and copy numbers on patient survival, we filtered out 
mutant allele frequencies at loci with |CNV| > 0.2 and calculated the log rank test for MATH using the remain-
ing sites (Fig. S13). Analysis of this set with multiple hypothesis correction did not yield any significant results, 
indicating that MATH clinical predictions are indeed driven by copy number aberrations. This result can be 
more clearly seen from the correlation between allele frequency variation and copy number variation. Pearson 
correlation coefficients between copy number standard deviation and MATH score were positive for all tumor 
types and all mutation callers (Fig. 4A). This effect was even stronger when we compared copy number standard 
deviation to allele frequency standard deviation (Fig. 4B). This further supports that allele frequency distributions 
are highly influenced by copy number aberrations across the genome (see examples in Fig. 4C,D).
To explore how the effect of copy number variation on phenotype is confounded by SNVs, we analyzed gene 
expression in UCEC (Fig. S14 and Methods). The expression levels of most genes (85%, Wilcoxon signed-rank test 
p = 9e−8) containing both SNVs and copy number amplifications was higher than genes lacking both changes, 
even after discarding tumor-suppressors and oncogenes (84%, p = 3e−6). However, amplified genes with SNVs 
were only slightly over-expressed compared to amplified genes without SNVs and this result was not statisti-
cally significant (60%, p = 0.38). This suggests that SNVs have a very minor effect on copy number amplification 
phenotype.
To fully decouple the effects of SNVs and CNVs, we calculated the whole genome CNV standard deviation 
(WG CNV std) by uniformly sampling the genome for copy number variations and calculating their correspond-
ing standard deviations (see Methods). We found that WG CNV std is highly correlated with CNV std (Spearman 
Figure 3. Significance analysis of measures of genomic variations and patient survival. (A) Survival analysis log 
rank test p-values for high and low MATH score groups, and (B) Survival analysis log rank test p-values for high 
and low CNV standard deviation groups. Stars corresponds to values smaller than significance threshold 0.05. 
Double stars show significant results after Benjamini-Hochberg correction across all cancer types and mutation 
callers.
www.nature.com/scientificreports/
5SCienTiFiC RepoRtS |  (2018) 8:11445  | DOI:10.1038/s41598-018-29154-7
correlation 0.93 for UCEC; Fig. S14), indicating an almost uniform distribution of SNVs across the genome. 
Similar to CNV std, increased WG CNV std also led to better patient survival in OV (log-rank p = 0.0009) and 
worse patient survival in UCEC (log-rank p = 0.0097), with the former showing significant results after multiple 
hypothesis correction (see Fig. S14). Overall, these results suggest that SNVs have a minor confounding effect on 
the clinical prognostic power of global copy number variation.
Distribution-based measures of intratumoral heterogeneity are consistent with many evolu-
tionary scenarios. The multiple contributions to MATH suggest a theoretical question: what is the unique-
ness of MATH score in distinguishing different underlying evolutionary scenarios? To answer this we considered 
the allele frequency distributions in the linear evolution model36 and computed MATH score as a function of 
model parameters, in the simplifying case of no CNVs. The linear model is the simplest model of tumor evolution 
with selection and assumes that occasional driver mutations lead to selective sweeps in a background of neutral 
mutations (Fig. 5A).
The allele frequency distribution can be specified by a variable w that we call the ‘neutral fraction’ (See 
Methods, eq. (9)), i.e. the fraction of total somatic mutations that occurred after the last selective sweep. We 
analytically derived a closed form for MATH score as a function of w (eq. (10)). Assuming exponential growth 
for time-dependence, there are a continuous set of choices of t1 (the time from the common ancestor of all tumor 
cells until the last selective sweep) and t2 (the time since the last selective sweep) that lead to identical values of 
w and MATH (Fig. 5B). Thus MATH score does not uniquely specify a tumor’s evolutionary history, even in the 
absence of copy number effects.
The model presented above is a simplification of one evolutionary scenario and can be influenced by several 
factors including mutation rate, proliferation rate and cell death. The derivation of eqs 9 and 10 assumes constant 
mutation rate per cell division after the last selective sweep, but does not put any restrictions on the form of the 
growth model, as long as the genotype and phenotype remain uncoupled37. Any global increase in growth rate 
or decrease in death rate after the last selective sweep is equivalent to an increase in the neutral fraction, w, and 
does not influence the model otherwise. On the other hand, changes in mutation rates can completely break down 
these derivations. One exception, however, is if the mutation rate changes during the last selective sweep and 
remains constant afterwards. An increase of mutation rate in this scenario would not violate model assumptions 
and is equivalent to an increase in the neutral fraction. Such a scenario may be relevant to some cancer types such 
as GBM38.
Figure 4. Correlation between allele frequency variations and copy number variations. (A) Pearson correlation 
coefficient of CNV standard deviation and MATH score. (B) Pearson correlation coefficient of CNV standard 
deviation and allele frequency standard deviation. (C) CNV standard deviation versus MATH score, plotted for 
HNSC (SNVs called by MuTect). Each circle is an individual sample. (D) CNV standard deviation versus allele 
frequency standard deviation, plotted for HNSC (SNVs called by MuTect).
www.nature.com/scientificreports/
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To understand the functional dependence of MATH on neutral fraction, we plotted it against w and com-
pared it to simulations (Fig. 5C). These results show two regimes of behavior across w. MATH score is zero when 
w ≤ 0.5 (the clonal regime – most mutations are clonal due to the sweep). Addition of measurement noise leads to 
an increase in MATH score in this clonal regime, but does not significantly affect MATH for w > 0.5 (the neutral 
regime – most mutations have evolved neutrally but vary in when they arose). In the neutral regime MATH is not 
a one-to-one function of w, and two very different allele frequency distributions can have the same score. These 
results show the limitations of single distribution-based scores to uniquely distinguish tumor evolutionary sce-
narios. Further features of the distribution, such as bimodality, should be used to resolve this degeneracy.
Discussion
In a pan-cancer analysis of 4722 samples we explored the robustness of allele frequency distributions to mutation 
calling and their power for clinical prediction. We demonstrated that the mutation calling process can signifi-
cantly influence the shape of allele frequency distributions. In general, higher variation in allele frequency was 
correlated with poorer survival, though this result was statistically significant in only a few cases. The only cancer 
type with statistically significant results robust across mutation callers was UCEC, but this reflected higher levels 
of copy number variation along the genome rather than increased subclonal heterogeneity. These results suggest 
that current single-variable measures of subclonal diversity from exome-seq data are not causally related to clin-
ical outcome.
To show the confounding effects of copy number variation on allele frequency distributions, we relied on a 
crude measure of genome-wide copy number variations (i.e. CNV standard deviation across SNVs), and showed 
that it is correlated with MATH and is predictive of patient survival in some cases. However, more in-depth 
analysis of copy number variations is required to fully explore the clinical relevance of CNV burden in tumors. 
Nevertheless, our results are consistent with copy number aberrations being a more important predictor of out-
come, which has previously been reported over pooled TCGA cancer types3. In our analysis most tumor types 
showed a regular, though not always statistically significant, trend between increased copy number variation and 
shorter survival time. Notably, high copy number variation has been previously reported to be associated with 
poor patient survival in serious endometrial carcinoma39. To determine the association between clinical features 
Figure 5. Theoretical analysis of MATH score. (A) Schematic diagram of linear tumor evolution model. t1 is the 
time from the common ancestor of all tumor cells until the last selective sweep. t2 is the time from the last 
selective sweep until biopsy. (B) Contour plots of neutral fraction, w, and MATH as a function of t1 and t2 for a 
noiseless exponentially growing model of linear evolution. w is the fraction of total SNVs that occurred after the 
last selective sweep. For this growth model, = +w t2 /( 2 )t t12 2 , where time is measured in cell cycles. (C) MATH 
score as a function of neutral fraction, w, for a linear tumor evolution model. Dashed lines correspond to 
analytical calculations. Green dots are samples from the model with 300 SNVs. Red dots are simulated results 
after incorporation of Gaussian measurement noise. Insets correspond to simulated allele frequency 
distributions for the two black circles, which have equal MATH scores.
www.nature.com/scientificreports/
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and CNV standard deviation, we also separately applied clinical feature selection (see Methods) to UCEC, and 
found that histologic diagnosis is the strongest predictor, with increased CNV variation for serous carcinoma 
(Fig. S15).
Ovarian cancer is opposite to the common copy number trend, in that tumors with more CNV variation are 
associated with longer survival. However, in ovarian cancer BRCA1 deletions often lead to the high-CNV tandem 
duplicator phenotype, and this phenotype has been found to have better clinical outcome40. Indeed, in the TCGA 
data we observe that increased deletions in BRCA1 are correlated with CNV standard deviation (Fig. S16), sug-
gesting that the ovarian cancer effect is mediated by the tandem duplicator phenotype.
Employing the full spectrum of allele frequency distributions in clinical studies would require multidimen-
sional survival analysis methods, which are sensitive to regression assumptions, or alternatively increasing sta-
tistical power by use of larger cohorts. Due to these limitations, in this paper we only focused on reduction of 
the distribution to a single quantity, namely MATH. Our analysis indicates that allele frequency distributions as 
quantified by MATH score are not useful clinical prognostic measures across cancer types. However, our work 
does not rule out the possibility of defining a set of clinically meaningful measures derived from allele frequency 
distributions. The issue however is that the space of possible measures is dramatically large, and, unless a more 
mechanism-driven approach is adopted, one would easily encounter underpowered statistics. To reflect this point 
we explored 11 extra statistics (Fig. S17) and found very little association to patient survival. The only exception 
was COAD when it was called by SomaticSniper.
A more direct measure of tumor heterogeneity is the cancer cell fraction (CCF), which is the fraction of 
cells having a specific SNV. We determined the CCFs for all cancers and mutation callers using PyClone7 (see 
Methods), and calculated MATH score using CCFs instead of allele frequencies (AF). We found that CCF MATH 
and AF MATH are positively correlated (Fig. S18, mean Pearson correlation coefficient 0.55, with minimum 0.30 
for HNSC-SomaticSniper, and maximum 0.82 for GBM-MuTect). Similar to AF MATH, higher CCF MATH was 
associated to poorer patient survival in UCEC-MuTect, however this result was not robust across mutation callers 
(Fig. S18).
In addition, we explored the importance of tumor purity on our results. Theoretically, tumor purity scales 
all mutant allele frequencies by a constant and should not affect MATH score. Order statistics such as KS test 
would not be affected by purity for a similar reason. However, dependence of mutation-calling errors on allele 
frequencies, and the removal of allele frequencies smaller than 0.1 in our pipeline are sensitive to purity scaling. 
To directly assess the effect of tumor purity we therefore compared MATH score against purity scores provided 
by TCGA, and found very little association between the two (−0.1 < r < 0.1, Fig. S19). Next, we removed sam-
ples with purity below 0.8 and compared allele frequency distributions across mutation callers. The results were 
similar to what we have described in Fig. 2. In the purity filtered datasets, survival analysis of MATH score did 
not lead to significant results for any cohort. As in the unfiltered analysis, CNV standard deviation was associated 
with patient survival in UCEC-MuTect and OV-SomaticSniper (Fig. S19).
Overall, we conclude that heterogeneity as quantified by MATH is not a strong predictor of patient survival, 
whether it is applied to allele frequencies or CCFs. CCF inference is prone to several errors, which can arise from 
many factors including strong priors in the inference algorithms, errors in allele frequency and copy number 
measurements, gross underestimation of SNV counts private to small subclones, and subsampling of the tum-
ors. Due to these issues CCF distributions may have unresolved prognostic powers which would require deeper 
genetic sequencing, use of more informative measures, and an increase in the number of patients and clinical 
data.
Despite these findings, we cannot conclude that subclonal heterogeneity is irrelevant to survival, as the pro-
cesses by which resistant populations develop remain poorly understood even though they are crucial to out-
come. For example, our work shows that gross estimates of subclonal heterogeneity from exome-seq data have 
little predictive power, but other studies have shown that resistance can arise from populations too small to be 
detectable by exome-seq41. Higher resolution measurements of subclonal heterogeneity may solve this challenge, 
and further development of robust computational analyses will be a critical part of such measurements.
Finally, we have shown that multiple evolutionary histories can lead to the same allele frequency distributions, 
and that different allele frequency distributions can have the same MATH score. This degeneracy of scenarios 
leading to the same measurement is an important reason why new descriptors of heterogeneity are needed. Future 
surveys over different evolutionary scenarios should be valuable for distinguishing what types of heterogeneity 
measurements are most likely to reveal features predictive of survival.
Conclusions
We studied the robustness of allele frequency distributions to mutation calling procedures across TCGA cancers 
and explored their prognostic power for patient survival. We found that mutation callers differ significantly in 
their estimates of the distributions of allele frequencies for individual tumors, and that the association between 
allele frequency distribution and survival is non-robust to these differences. The major exception is uterine cor-
pus endometrial carcinoma, but the observed effect is mediated by copy number variation rather than subclonal 
heterogeneity. Our work has implications for cancer precision medicine, as we show that current measures of 
heterogeneity are not predictive of survival except through an indirect association with copy number variation.
Methods
Computational Time. The average time required to run a task was 2 hours and 25 minutes. We ran a total of 
14865 jobs, with total wall time of 1496 days.
Sample Selection. Samples were chosen only if tumor/normal Illumina exome-seq data existed with align-
ment to hg19, and corresponding clinical and Affymetrix SNP Array somatic copy number variation data were 
www.nature.com/scientificreports/
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present. SNVs were called by three mutation callers and samples were discarded if any mutation caller did not 
find any somatic SNVs in that sample. If multiple normal samples were available, blood has been preferred over 
solid tissue. For tumors, primary solid tumor was used if available. The main anomaly was in SKCM, where most 
TCGA samples are metastatic (Fig. S2).
Mutation Caller Parameters. Mutation calling was done with minor tweaks to the default parameters of 
each mutation caller (Table 1). For MuTect, these flags control proximal gaps, poor mapping quality, strand bias, 
clustered positions, mutations in normal sample, low tumor/normal mutation likelihood ratio, and presence in 
dbsnp. For SomaticSniper we set parameters to ignore loss of heterozygosity and gain of reference. Furthermore 
SomaticSniper uses a Phred-scaled value, ‘somatic score’, to determine somatic mutations. We have used a 
high-confidence threshold for this value to improve precision of the algorithm (−Q 40). The parameters for 
VarScan set minimum for coverage and allele frequency to limit the number of reported mutations. However 
these parameters will be overridden in the post-processing step.
Postprocessing Filters. We applied post-processing filters on the output VCF files to extract the somatic 
SNVs. For MuTect and VarScan we selected SNVs with FILTER = PASS, and in all cases we only used SNVs which 
had zero allele frequency for normal sample and a non-zero value for the tumor. A read depth filter of minimum 
50 was also applied to both normal and tumor samples. Furthermore, we discarded SNVs which had tumor or 
normal allele frequency < .0 1. For more detail on mutation calling process and parameters see Fig. S1 and Table 1.
Statistical Distances. To calculate the earth mover’s distance (EMD)42, we produced histograms of allele 
frequencies for each sample using bins of size .0 025 and followed the procedure in43 for chain-connected spaces. 
For two probability distributions f x( )1  and f x( )2  with respective normalized histogram abundances f j1,  and f j2,  at 
j’th bin (with ≤j N), EMD can be written as43:
∑∑= | − |
=
−
=
f f f fEMD( , )
(2)i
N
j
i
j j1 2
1
1
1
1, 2,
Quantities reported in this paper are the median of this value across each cohort (Fig. 2C).
We also used another method for quantifying differences between distributions of allele frequencies, where we 
smoothed the histogram of allele frequencies using Gaussian kernel density estimation with standard deviation 
σ = .0 02, leading to two continuous functions f x( )1  and f x( )2 . We then calculated the cumulative absolute differ-
ence of these two functions using ∫ | − |f x f x dx( ) ( )0
1
1 2 . Again the median of cohort was calculated as a single 
measure of statistical distance (Fig. S5).
Finally, we also used a non-parametric statistical distance between allele frequency distributions which relies 
on the average L2 distance between two distribution functions35. The statistic is defined as ∫ −f x f x dx[ ( ) ( )]0
1
1 2
2 , 
where f x( )1  and f x( )2  are the Gaussian kernel density estimations of the two functions (bandwidth = 0.05). We 
calculated the corresponding p-values by applying a permutation test to each pair of allele frequency sets for 
which the test statistic was being calculated. This procedure was repeated 100 times and the ratio of tests which 
were more extreme than the non-permuted test was reported as the p-value.
Allele Frequency and Read Depth. Read depth and allele frequency were extracted from the FORMAT 
field of VCF files. Multiallelic and biallelic sites were treated similarly and their allele frequencies corresponded to 
the ratio of alternative alleles to reference alleles. For MuTect and VarScan the allele frequency computed by the 
Caller Parameters
MuTect  
1.1.7
default ( 
tumor_1od = 6.3  
fraction_contamination = 0.02  
normal_1od = 2.2  
strand_artifact_lod = 2.0  
strand_artifact_power_threshold = 0.9  
dbsnp_normal_1od = 5.5  
gap_events_threshold = 3  
fraction_mapq_threshold = 0.5  
pir_median_threshold = 10.0  
pir_mad_threshold = 3.0  
required_maximum_alt_allele_mapping_quality_score = 20  
max_alt_alleles_in_normal_count = 2  
max_alt_allele_in_normal_fraction = 0.03 
)
SomaticSniper  
1.0.5.0 -Q 40 -L -G
VarScan  
2.3.9
somatic  
–min-coverage 10  
–min-coverage-normal 10  
–min-coverage-tumor 10  
–min-var-freq 0.05
Table 1. Mutation caller parameters.
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software was directly extracted from VCF files, and for SomaticSniper this was done by using the reference and 
alternative read counts reported by the software.
Copy Number Data. For copy number analysis we used masked copy number level 3 TCGA data measured 
by Affymetrix SNP Array 6.0 which is readily aligned to hg19 and normalized for somatic copy number detection 
by removal of frequent germline copy number variations. The quantity used throughout the paper is the Segment 
Mean column in the ‘nocnv’ files which is either used directly or determined at the SNV locus of interest. This 
quantity is the average log2 ratio of copy number of the tumor compared to reference (=2) within a segment of 
the genome where internal changes are minimal. Positive values correspond to amplification and negative values 
correspond to deletion. Wherever mentioned in the text, copy number filtering was done according to44 where 
loci with | | > .CNV 0 2 were removed.
Survival Data. Survival information was gathered from the TCGA data portal by parsing the clinical json 
files for field diagnoses.days_to_death as survival time. In cases where this field was not available, we used diag-
noses.days_to_last_follow_up instead. The field diagnoses.vital_status was used for determining censored data.
Survival Analysis. Survival analysis was done using Kaplan-Meier curves and log rank test method from the 
Lifelines Python package45. Only the first 4 years of survival information was used for analyses and any sample 
with longer overall survival was censored at this time point.
Survival difference values (Fig. S10) were defined by calculating the Kaplan-Meier curves (Figs S8, S11) for 
two groups with high and low variability score (divided across the median of the score used). We then integrated 
the absolute value of difference of survival functions:
∫ −T S t S t dt
1 [ ( ) ( )]
(3)max
T
High Low
0
max
where S t( )High  and S t( )Low  are the survival functions of the two groups and Tmax corresponds to the maximum time 
of data collection (4 years). This definition leads to a quantity between 1−  and 1 which is more negative if the high 
score group has worse survival, and more positive if the high score group has better survival.
Expression Analysis. To determine how copy number amplification influences expression, we downloaded 
the corresponding RNAseq expression results (RPKM values) of UCEC for each sample from the TCGA database.
For gene g  in patient p, let matrices rp g, , cp g, , and sp g,  respectively be the RPKM value, CNV value, and SNV 
status (1 if mutated, 0 otherwise) of the gene. Furthermore, for total of N  patients let us define x( )p g,  as the aver-
age of positive elements of matrix xp g,  along the columns:
≡
∑
∑
=
=
x
x
u x
( )
( ) (4)
p g
p
N
p g
p
N
p g
,
1 ,
1 ,

where = ≤> .{u x xx( ) 0, 0,1, 0  is a step function that includes the zero coordinate. The reason for this definition of 
 x( )p g, , is to calculate few different versions of gene expression averages across cohorts based on different criteria 
illustrated below:
 1. mean RPKM (amplified, with SNV):
 r u c c s( ( ) ) (5)p g p g
th
p g, , 2 ,× − ×
 2. mean RPKM (not amplified, without SNV):
 r u c c s( ( ) (1 )) (6)p g
th
p g p g, 1 , ,× − × −
 3. mean RPKM (amplified, without SNV):
 × − × −r u c c s( ( ) (1 )) (7)p g p g
th
p g, , 2 ,
Here × is ordinary element-wise product. = .c 0 1th1  and = .c 1 0
th
2  are the CNV thresholds for no amplification 
and amplification respectively. Note that since amplified SNVs are rare, the averaging in equation (5) could be 
dropped, rendering this quantity effectively as the single gene RPKM. Furthermore, in cases that the denominator 
of equation (4) is zero (i.e. no sample meets the criteria), the gene is discarded. Associations between these expres-
sion values are reported in Fig. S14.
To determine the effects of tumor suppressors and oncogenes on expression results, we downloaded the list 
of tumor-suppressor genes from TSGene46,47 and oncogenes from ONGene48 and removed the genes existing in 
either of the lists.
CNV Standard Deviations. Throughout the text CNV standard deviation (std) of a sample is calculated as 
the standard deviation of CNVs at all loci that have an SNV.
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On the other hand, whole genome (WG) CNV standard deviation is calculated independent of SNVs, by 
uniform sampling of the genomic regions for which copy number information is available. Equivalently, we can 
write:
∑= −
=
p c cWG CNV std ( )
(8)i
N
i i
1
2
where = ∑ =c p ciN i i1  is the mean CNV across the genome, ci is the CNV of copy number segment i, N is the total 
number of segments, and = ∑ =p l l/i i j
N
j1  is the fraction of genome covered by segment i with genomic length li.
Mathematical Modeling. The mathematical model presented in this paper is a linear of model of tumor 
evolution36, where any driver mutation leads to a selective sweep and the remaining mutations are passenger 
mutations. All the mutations before the last selective sweep are clonal with allele frequency 0.5. The remaining 
mutations follow the neutral model, with cumulative distribution of allele frequency f  proportional to f1/ 24. Then, 
the overall allele frequency distribution is the combination of these two distributions sampled according to their 
occurrence rates (see Supplementary Material):
( )P F f
f f
f f
f
( )
0, ,
, 0 5,
1, 0 5 (9)
min
f f min2
1 1
min
≤ =




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<
− ≤ < .
= . .
ν
where ν =
−
wf
f
2
1 2
min
min
, w is the ‘neutral fraction’ and is defined as the fraction of all mutations that are neutral, and 
fmin is the minimum measurable allele frequency. The latter quantity is necessary in order to avoid singularity at 
=f 0. In our simulations we set = .f 0 1min . The results of simulations with no measurement noise (Fig. 5C) were 
calculated using 300 samples from this distribution, and their variations reflect this sampling error.
We derived a closed form for MATH score of the model as a function of w (see Supplementary Material for 
derivation):
w
w w
w w
MATH 148 26
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2
,
1
2
1, 1
2
1
2
,
, 1
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.
The allele frequency measurement error can be modeled by a binomial distribution, where observing a muta-
tion on a sequencing read is a Bernoulli trial. For TCGA whole exome sequencing, read depths are quite large (on 
average 100×) and this error can be approximated by a Gaussian distribution. Therefore, to implement allele 
frequency noise we drew 300 samples from the distribution in equation (9) and used each resulting value f  to 
sample from the normal distribution  −( )f , f fN(1 ) . Here =N 100 is the sequencing read depth.
Cancer Cell Fractions. To determine cancer cell fractions (CCF), we used PyClone7 in the allele-agnostic 
mode by setting the flag ‘–prior’ to ‘total_copy_number’. For input tsv files, we set normal_cn = 2, minor_cn = 0, 
and major_cn = round ×(2 2 )CNV , where in the latter equation, CNV is the log2 ratio segmentation information 
from TCGA SNP Array data. In a few samples a small number of loci had major_cn = 0. We removed these loci 
from our analysis. Furthermore, to speed up PyClone runtime, if a sample had more than 500 SNVs we randomly 
removed excess loci.
Alignment to GRCh38. Genomic alignments can lead to different SNVs and/or allele frequencies, depend-
ing on read quality and genomic repeats. As a confirmatory step we explored this effect by comparing our results 
for selected samples against alignments to the new human genome (hg38). To achieve this, we downloaded 
227 TCGA breast cancer BAM files of whole exome sequencing data from Cancer Genomics Hub (CGHub)49. 
After converting the BAM files to FASTQ files, we remapped the FASTQ files to hg38 reference genome with the 
Burrows-Wheeler Aligner (BWA)50. The somatic SNVs were called by MuTect28. We found that the allele distri-
butions contained less SNVs overall, but their shapes were relatively similar (Fig. S20).
Clinical Feature Selection. Random forest feature selection of clinical data (Fig. S15) was done using 
ExtraTreesClassifier function from Python package scikit-learn51, with default parameters and 250 estimators. 
Features with 20% or more unknown values were discarded and the remaining unknown values were set to the 
median of the feature for numerical features or the mode for categorical features. Data labeling was done by com-
paring CNV standard deviation to its median.
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